Natera, Inc.?has partnered with?Fox Chase Cancer Center, one of the leading cancer centers in?the United States, to assess the company's?Signatera??(Research-Use Only) customized circulating tumor DNA (ctDNA) assay for recurrence monitoring of kidney canc